Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

2-Methoxyestradiol - CASI Pharmaceuticals

Drug Profile

2-Methoxyestradiol - CASI Pharmaceuticals

Alternative Names: 2ME2; CASI-2ME2; Panzem; Panzem® Capsules; Panzem® NCD

Latest Information Update: 24 Jul 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Childrens Hospital Boston; Harvard Medical School
  • Developer CASI Pharmaceuticals; EntreMed
  • Class Antineoplastics; Estradiol congeners; Estrenes; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Hypoxia-inducible factor-1 alpha inhibitors; Lymphocyte inhibitors; Mitosis inhibitors; NFATC transcription factor inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Ovarian cancer; Multiple myeloma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Autoimmune disorders; Rheumatoid arthritis
  • Discontinued Age-related macular degeneration; Breast cancer; Carcinoid tumour; Cardiovascular disorders; Endometriosis; Glioblastoma; Multiple myeloma; Osteoporosis; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 20 Jul 2015 Suspended - Preclinical for Autoimmune disorders in USA (PO) before July 2015
  • 27 Mar 2015 CASI Pharmaceuticals plans a phase I pharmacokinetic trial
  • 16 Jun 2014 EntreMed is now called CASI Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top